Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus MONJUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus MONJUVI.
ARRANON vs MONJUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
MONJUVI (tafasitamab-cxix) is a humanized Fc-engineered CD19-directed cytolytic monoclonal antibody. It binds to CD19 antigen on the surface of pre-B and mature B lymphocytes, and upon binding, facilitates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
3 mg/kg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Terminal half-life: approximately 17 days (range 11-27 days). This supports a dosing interval of every 2 weeks, as steady state is reached by approximately 70 days.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Monjuvi (tafasitamab-cxix) is a monoclonal antibody primarily catabolized into small peptides and amino acids. No specific data on renal or biliary excretion; minimal intact drug excreted in urine or feces. Expected to undergo general protein degradation.
Category C
Category C
Antineoplastic
Antineoplastic